Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial NEET proteins, also known as CDGSH iron-sulfur domain-containing (CISD) proteins, are a unique class of [2Fe-2S] cluster-binding proteins located primarily in the mitochondria and endoplasmic reticulum. The family consists of three members in humans: CISD1 (mitoNEET), CISD2 (NAF-1), and CISD3 (Miner2), which play critical roles in regulating mitochondrial iron homeostasis, reactive oxygen species (ROS) levels, and bioenergetics (PMID: 17360355, 21825116). These proteins act as redox-sensitive switches that can transfer their iron-sulfur clusters to acceptor proteins, thereby modulating cellular pathways such as apoptosis, autophagy, and ferroptosis. Dysregulation of NEET proteins is implicated in a wide range of pathologies, including type 2 diabetes, neurodegenerative disorders like Parkinson's disease, and various cancers where they support tumor cell proliferation (PMID: 33184277, PMC8021574). NEET proteins were first identified as the mitochondrial targets of the thiazolidinedione class of anti-diabetic drugs, such as pioglitazone, which stabilize the [2Fe-2S] cluster and mitigate mitochondrial dysfunction (PMID: 17360355). Recent therapeutic strategies focus on developing small molecules that either stabilize or destabilize these clusters to treat metabolic diseases or induce ferroptosis in cancer cells. For instance, molecules like Mito-C and M1 have been designed to modulate mitochondrial morphology and iron levels, offering potential treatments for viral infections and metabolic syndrome (PMID: 33184277). Given their central role in maintaining organelle crosstalk and cellular health, NEET proteins represent a promising frontier for disease-modifying therapies in aging and chronic metabolic conditions.
Drugs targeting NEET proteins typically act by stabilizing or destabilizing the [2Fe-2S] cluster within the CDGSH domain, thereby modulating the rate of cluster transfer to acceptor proteins and regulating mitochondrial iron and ROS levels.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CDGSH iron-sulfur domain-containing protein (NEET protein) (NEET).